House Enrolled Act 1218 Summary

• Opioid treatment programs must periodically and randomly test patients for methadone, cocaine, opiates, amphetamines, barbiturates, tetrahydrocannabinol, benzodiazepines, and other suspected drugs during treatment.

• Reduces the threshold requiring prior division authorization for take-home opioid medications from 14 days to 7 days of supply, with authorization contingent on physician order, negative drug test results, and documented benefit outweighing diversion risk.

• Authorizes opioid treatment programs to use buprenorphine and buprenorphine combination products containing naloxone as alternatives to methadone, subject to FDA approval and division approval.

• Requires opioid treatment programs to report medication dispensing data to the division including medications, delivery forms, doses, dosages, take-home patient counts, supply days, patient demographics, and DEA registration numbers.

• Mandates study of including all prescription drugs in the INSPECT prescription monitoring program by October 1, 2014, and legislative interim committee review of whether to prohibit multiple-day take-home supplies at opioid treatment programs.